RT Journal Article
SR Electronic
T1 Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21250357
DO 10.1101/2021.04.26.21250357
A1 Goubet, Anne-Gaëlle
A1 Dubuisson, Agathe
A1 Geraud, Arthur
A1 Danlos, François-Xavier
A1 Terrisse, Safae
A1 Alves Costa Silva, Carolina
A1 Drubay, Damien
A1 Touri, Lea
A1 Picard, Marion
A1 Mazzenga, Marine
A1 Silvin, Aymeric
A1 Dunsmore, Garett
A1 Haddad, Yacine
A1 Pizzato, Eugenie
A1 Ly, Pierre
A1 Flament, Caroline
A1 Melenotte, Cléa
A1 Solary, Eric
A1 Fontenay, Michaela
A1 Garcia, Gabriel
A1 Balleyguier, Corinne
A1 Lassau, Nathalie
A1 Maeurer, Markus
A1 Grajeda-Iglesias, Claudia
A1 Nirmalathasan, Nitharsshini
A1 Aprahamian, Fanny
A1 Durand, Sylvère
A1 Kepp, Oliver
A1 Ferrere, Gladys
A1 Thelemaque, Cassandra
A1 Lahmar, Imran
A1 Fahrner, Jean-Eudes
A1 Meziani, Lydia
A1 Ahmed-Belkacem, Abdelhakim
A1 Saïdani, Nadia
A1 La Scola, Bernard
A1 Raoult, Didier
A1 Gentile, Stéphanie
A1 Cortaredona, Sébastien
A1 Ippolito, Giuseppe
A1 Lelouvier, Benjamin
A1 Roulet, Alain
A1 Andre, Fabrice
A1 Barlesi, Fabrice
A1 Soria, Jean-Charles
A1 Pradon, Caroline
A1 Gallois, Emmanuelle
A1 Pommeret, Fanny
A1 Colomba, Emeline
A1 Ginhoux, Florent
A1 Kazandjian, Suzanne
A1 Elkrief, Arielle
A1 Routy, Bertrand
A1 Miyara, Makoto
A1 Gorochov, Guy
A1 Deutsch, Eric
A1 Albiges, Laurence
A1 Stoclin, Annabelle
A1 Gachot, Bertrand
A1 Florin, Anne
A1 Merad, Mansouria
A1 Scotte, Florian
A1 Assaad, Souad
A1 Kroemer, Guido
A1 Blay, Jean-Yves
A1 Marabelle, Aurélien
A1 Griscelli, Frank
A1 Zitvogel, Laurence
A1 Derosa, Lisa
YR 2021
UL http://medrxiv.org/content/early/2021/05/05/2021.04.26.21250357.abstract
AB Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19+), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T helper cells, and non-naive Granzyme B+ FasL+, EomehighTCF-1high, PD-1+CD8+ Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04341207Funding StatementThe Gustave Roussy sponsored clinical study on COVID-19 (ONCOVID; NCT NCT04341207 has been supported by the Fondation Gustave Roussy, the Dassault family, Malakoff Humanis, Agnes b., Izipizi, Ralph Lauren and Sanofi).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written informed consent. Protocol approval was obtained from an independent ethics committee (ethics protocol number EudraCT No: 2020-001250-21). Gustave Roussy Data Protection Officer (DPO) has evaluated this project and sent to the principal investigator a formalized-operational action plan about data protection compliance: patient's information, security measures, good practices about pseudonymization, etc. All of the DPO's recommendations has been applied by the research team.In agreement with MR004 in France, we reported the series to the national information science and liberties commission. Ethic committees: The Agence Nationale de securite du medicament et des produits de sante (FRANCE) gave the approval for the clinical trial No. EudraCT 2020-001250-21 (reference: MEDAECPP-2020-03-0012). The Committee of the Convention for the Protection of Individuals CPP Ile de France XI (FRANCE) approved the clinical trail (reference: 20025-75647). Decision made: CPP Ile de France XI and Agence Nationale de securite du medicament et des produits de sante authorized Gustave Roussy (No. CSET 2020/3078) for the clinical trial ONCOVID.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and materials availability: This study includes no data deposited in external repositories.Abbreviations in alphabetic orderACE2Angiotensin-Converting Enzyme 2CDcluster of differentiationcMoclassical monocytesCOVID-19severe coronavirus infectious disease 2019CtCycle thresholdCRClinical RoutineCXCR5C-X-C chemokine receptor type 5ECOGEastern Cooperative Oncology Group performance statusEMeffector memory cellsEomeseomesoderminFCfold changeFasLFas ligandGzBgranzyme BHCWhealth care workerICOSInducible T-cell co-stimulatorICUintensive care unitIFNInterferonIgImmunoglobulinILinterleukinLVSlong term viral RNA sheddingNKNatural killernon-cMonon classical monocytesNSMNon-switch MemoryOrf1breplicase open reading frame 1bPDprogressive diseasePD-1programmed cell death 1PMNpolymorphonuclear cellsRBDreceptor-binding domainRdRPRNA-dependent RNA polymeraseRNAribonucleic acidrIL-7recombinant interleukin 7RT-qPCRquantitative reverse transcription-polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2SDstable diseaseSVSshort term viral RNA sheddingTc1cytotoxic T lymphocytesTCF-1Transcription factor 1TFHT follicular helper cellsTRTranslational Research.